The company is a high-tech enterprise jointly recognized by Tianjin Science and Technology Commission, Tianjin Finance Bureau, Tianjin State Taxation Bureau and Tianjin Local Taxation Bureau. It owns 13 patents (including 9 invention patents, 3 utility model patents and 1 piece of design patents), and has accepted 18 invention patents, and applied for scientific research topics such as the Ministry of Science and Technology, the National Development and Reform Commission and the Tianjin Municipal Science and Technology Commission. Including 18 innovation fund projects for small and medium-sized scientific and technological enterprises, major national scientific and technological projects, transformation projects of scientific and technological achievements, and national investment plans for the development of high-tech industries. The company has 8 national new drug certificates, and the drug approval number is 2 1, and all the dosage form production workshops have passed GMP certification. At present, the company has obtained 30 registered trademarks, including one well-known trademark (Xuebijing)/kloc-0 and two famous trademarks (Hongri and Chuanwei) in Tianjin.
Hongri Pharmaceutical Co., Ltd. is the first GEM enterprise in China and the first GEM enterprise in Tianjin. Known as "the first venture in Golden Gate", it was once listed in the list of potential enterprises in China by Forbes, selected as the top 20 GEM companies in the "20 12 China Listed Companies Value Selection" and ranked seventh in the top 20 most competitive pharmaceutical listed companies in the 5th China. As of August/4, 2065438, the total market value of Hongri Pharmaceutical was 15 1 100 million, ranking sixth among 38 listed companies in Tianjin and 1 1 among the listed companies on Growth Enterprise Market.
The company is mainly engaged in the research, development, production and sales of Chinese patent medicines and western medicines. Its leading products are Xuebijing injection and Fasudil hydrochloride injection, including Chinese medicine formula granules produced by Beijing Kangrentang Pharmaceutical Co., Ltd., a wholly-owned subsidiary. Xuebijing injection is the only national second-class new drug approved by SFDA to treat sepsis and multiple organ dysfunction syndrome in China, with clear treatment mechanism and remarkable treatment effect, and has a monopoly position in the market segment; The company owns the independent intellectual property rights of the drug and two national invention patents; The research, development and industrialization of the drug were supported by the National Development and Reform Commission's "National Investment Plan for High-tech Industry Development" and the Ministry of Science and Technology's "Innovation Fund Project for Small and Medium-sized Sci-tech Enterprises". It won the first prize of Tianjin Excellent Technological Innovation Project in 2006, the second prize of Science and Technology Award issued by China Association of Integrated Traditional Chinese and Western Medicine, the second prize of Tianjin Patent Excellence Award in 2007 and the second prize of Tianjin Scientific and Technological Progress Award in 2008. In May 2006, it was jointly recognized as a "secret" by the Ministry of Science and Technology and In 2009, it was selected as a Chinese medicine treatment drug based on syndrome differentiation by the Ministry of Health's "Influenza A H 1N 1 Diagnosis and Treatment Plan (second edition trial in 2009)".
Fasudil hydrochloride injection is a second-class new drug in China and the first Rho kinase inhibitor in China. Our company is the first enterprise in China to produce this kind of raw materials and injections, and the new drugs have a four-year transition period. The research, development and industrialization of the drug have been supported by the Innovation Fund for Small and Medium-sized Sci-tech Enterprises of the Ministry of Science and Technology and the Achievement Appraisal Project of Scientific and Technological Achievements Transformation Project of Tianjin Science and Technology Commission. And won the first prize of Tianjin excellent technological innovation project in 2007 and the second prize of Tianjin scientific and technological progress in 2008.
The company has always adhered to the concept of "pursuing excellent quality and creating a healthy life" and achieved remarkable results under the guidance of targeted academic marketing. In addition, the company did not forget to repay the society, and made many donations and materials, which gained a good reputation and was widely recognized by all sectors of society.
On June 30th, 2009, 10, the company was officially listed on the Growth Enterprise Market of Shenzhen Stock Exchange. Grasping this development opportunity, the company has comprehensively improved the research and development capacity, production capacity, operating efficiency, market share and profitability of new drugs through technological innovation, management innovation, professional academic promotion and fund-raising project construction, and achieved good results. In the future, the company will continue to consolidate and develop the overall strength and competitiveness of enterprises, and repay society and society.